固本平喘汤在稳定期慢性阻塞性肺疾病中的应用效果及安全性分析  

Analysis of Therapeutic Effect and Safety of Guben Pingchuan Decoction in Treating Stable Chronic Obstructive Pulmonary Disease

作　　者：彭俊杰 彭智勇 迟林园 李竺宜 PENG Jun-Jie;PENG Zhi-Yong;CHI Lin-Yuan;LI Zhu-Yi(Bao’an Traditional Chinese Medicine Hospital Affiliated to Guangzhou University of Chinese Medicine,Shenzhen 518100 Guangdong,China)

机构地区：[1]广州中医药大学附属宝安中医院,广东深圳518100

出　　处：《广州中医药大学学报》2022年第1期37-41,共5页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：深圳市卫生计生委科研项目(编号:SZFZ2017103)。

摘　　要：【目的】观察固本平喘汤联合常规西医治疗稳定期慢性阻塞性肺疾病(COPD)肺肾气虚证患者的疗效及安全性。【方法】将60例稳定期COPD肺肾气虚证患者随机分为试验组和对照组,每组各30例。对照组给予健康管理与常规西医治疗,试验组在对照组的基础上联合固本平喘汤治疗,疗程为3个月。观察2组患者治疗前后血清白细胞介素8(IL-8)、肿瘤坏死因子α(TNF-α)等炎症因子水平的变化情况,比较2组患者治疗期间急性加重情况、临床疗效和安全性。【结果】(1)治疗3个月后,试验组的总有效率为93.33%(28/30),对照组为73.33%(22/30);组间比较,试验组的疗效明显优于对照组(P<0.05)。(2)治疗期间,试验组患者的急性加重次数少于对照组(P<0.01),平均住院时间短于对照组(P<0.01)。(3)治疗后,2组患者血清IL-8、TNF-α水平均较治疗前明显降低(P<0.05),且试验组的降低作用均明显优于对照组(P<0.01)。(4)治疗期间,2组均未发生严重不良反应,仅试验组有2例出现轻度一过性不适,未给予特殊干预,均不影响正常治疗。【结论】固本平喘汤联合常规西医治疗稳定期COPD肺肾气虚证患者安全、有效,有利于防治COPD患者的急性加重,其可能与下调血清炎症介质表达有关。Objective To observe the clinical efficacy and safety of Guben Pingchuan Decoction(a herbal compound prescription mainly with the actions of consolidating vital base and relieving asthma)combined with conventional western medicine in the treatment of stable chronic obstructive pulmonary disease(COPD)patients with lung-kidney qi deficiency syndrome. Methods Sixty stable COPD patients with lung-kidney qi deficiency syndrome were randomly divided into the trial group and the control group, with 30 cases in each group. The control group was given health management and conventional western medicine,and the trial group was treated with Guben Pingchuan Decoction on the basis of treatment for the control group. The course of treatment lasted for3 months. The serum levels of inflammatory factors of interleukin 8(IL-8)and tumor necrosis factor alpha(TNF-α)were observed in the two groups before and after treatment, and the acute exacerbation during the treatment,clinical efficacy and safety were compared between two groups. Results(1)After 3 months of treatment,the total effective rate of the trial group was 93.33%(28/30), and that of the control group was 73.33%(22/30). The intergroup comparison showed that the therapeutic effect of the trial group was significantly superior to that of the control group(P <0.05).(2)During the treatment,the frequency of acute exacerbations in the trial group was less than that in the control group(P<0.01),and the average hospitalization time was shorter than that in the control group(P<0.01).(3)After treatment, the levels of serum IL-8 and TNF-α in the two groups were significantly decreased compared with those before treatment(P<0.05),and the effect on lowering the serum IL-8 and TNF-α levels in the trial group was significantly superior to that in the control group(P<0.01).(4)During the treatment,there were no serious adverse reactions occurred in the two groups,while only 2 cases in the trial group showed mild transient discomfort without the meeding of special intervention,which had

关 键 词：稳定期慢性阻塞性肺疾病(COPD) 肺肾气虚证 固本平喘汤 急性加重 炎症因子 

分 类 号：R259.63[医药卫生—中西医结合]